

## XVIVO Perfusion – Consensus estimates Q1 2025

Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.

Number of contributors: 7 (all of which have been updated or confirmed before the report)

KPI (MSEK, unless otherwise specified)	Q1 2025E
Net sales	213
Organic growth in local currency (%)	13.00
Gross profit	159
EBITDA	43.2
EBIT	25.3
Net profit	23.6
Earnings per share (SEK)	0.75

XVIVO Perfusion's Q1 report will be released on Thursday, 24 April 2025 at 07.30 CEST.